Trial Profile
Mesenchymal stromal stem cell therapy (Cyndacel-M) in a flowable dermal matrix (Excellagen) for chronic diabetic wounds.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2014
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Chronic wounds
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gene Biotherapeutics; Orbsen Therapeutics
- 26 Jun 2014 New trial record